Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PF-07220060 + PF-07104091 plus endocrine therapy in advanced HR-positive breast cancer and solid tumors
2023-509504-15-00Phase 2Authorised
- Sponsor
- Pfizer
- Start
- Jun 2024
- Modality
- Small Molecules
- Countries
- 9
01
Overview
Phase 2, open-label trial of atirmociclib and tegtociclib in breast cancer and Nonhematologic neoplasms (2 arms), sponsored by Pfizer. Primary endpoints: First cycle dose-limiting toxicities (DLTs) - Part 1, Adverse events (AEs) - Part 1 and 6 more. Planned start Jun 2024; status: authorised.
02
Drugs
atirmociclibtegtociclib
03
Conditions
breast cancerNonhematologic neoplasms
Beyond the preview
Go deeper on 2023-509504-15-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-509504-15-00.